New York's pharmaceuticals companies play a crucial role in health care, focusing on drug development and delivery. This sector is primarily composed of both large corporate entities and smaller, innovative startups. Companies specialize in various therapeutic areas including oncology, generics, and specialty medications, addressing the global challenge of disease treatment. The industry is increasingly leaning towards personalized medicine and biotechnological advancements. As patient care becomes more individualized, companies here are exploring opportunities in digital health, aiming to enhance both accessibility and effectiveness of therapies. Notably, New York is fostering collaborations between academic institutions and industry players, accelerating innovation.

The companies listed vary significantly in size, with some employing just a handful of staff while others boast thousands. Locations range from New York City to smaller towns, showcasing a widespread operation footprint. Founded between 1976 and 2021, these firms include both family-owned and corporate entities. They offer a wide array of products—from generic medications to specialized therapies—highlighting their adaptability and focus on addressing pertinent health issues.

Continue reading for a closer look at New York's top pharmaceuticals companies.

Top 24 Pharmaceuticals Companies in New York

1. Par Pharmaceutical

• Website: parpharm.com
• Ownership type: Corporate
• Headquarters: Chestnut Ridge, New York, United States (USA)
• Employee distribution: India 57%, United States (USA) 42%
• Latest funding: $8.1B, May 2015
• Founded year: 1978
• Headcount: 501-1000
• LinkedIn: par-pharmaceutical

Par Pharmaceutical, part of Endo International plc, is a pharmaceutical company based in Chestnut Ridge, New York. Founded in 1978, the company specializes in developing and delivering therapies that enhance the quality of life for patients. Their product offerings include specialty medicines, sterile injectables, and generic pharmaceuticals, catering to healthcare providers, hospitals, and patients. Par Pharmaceutical is particularly focused on areas such as urology, orthopedics, and pediatric endocrinology, addressing specific medical needs with targeted solutions. The company operates a robust manufacturing network, ensuring compliance with industry standards and maintaining a commitment to quality. With a workforce of approximately 1,415 employees, Par Pharmaceutical has a significant presence in both the United States and India, reflecting its global operational strategy. Their ongoing research and development efforts aim to discover innovative treatments, with a pipeline that includes numerous products designed to meet the needs of patients and healthcare providers alike.

2. Ichnos Sciences

• Website: ichnossciences.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: ichnos-sciences

Ichnos Sciences, also known as Ichnos Glenmark Innovation, is a biotechnology and pharmaceutical company based in New York, New York. Founded in 2019, the company is dedicated to developing innovative therapy solutions specifically targeting hematological malignancies and solid tumors. Ichnos Sciences operates with a clear focus on improving patient outcomes in oncology through advanced treatment options. The company collaborates with healthcare professionals and organizations to enhance its research and development efforts. Ichnos has established three centers of innovation located in the USA, Switzerland, and India, which support its clinical development and research initiatives. Their current pipeline includes several promising candidates in Phase 1 trials, such as ISB 1442 and ISB 2001, indicating an active commitment to bringing new therapies to market. The leadership team boasts extensive experience in drug development and immuno-oncology, further solidifying the company's position in the pharmaceutical sector.

3. PL Developments

• Website: pldevelopments.com
• Ownership type: Family Owned
• Headquarters: Westbury, New York, United States (USA)
• Employee distribution: United States (USA) 99%, Other 1%
• Latest funding: Other (Debt), $500.0M, October 2024
• Founded year: 1988
• Headcount: 1001-5000
• LinkedIn: pl-developments

PL Developments, founded in 1988 and based in Westbury, New York, is a family-owned pharmaceutical manufacturer. The company specializes in the development and production of over-the-counter health and beauty products, catering to major retailers and consumers alike. Their product offerings include allergy medications, analgesics, cough and cold remedies, digestive aids, feminine care products, first aid items, personal care solutions, nicotine replacement therapies, and sleep aids. With a workforce of over 500 employees, PL Developments emphasizes quality in both its products and its relationships with clients and suppliers. The company has also engaged in contract manufacturing and packaging for other major OTC and nutritional companies, showcasing its operational capabilities. Recently, PL Developments secured $500 million in funding, indicating a strong financial position and potential for further growth in the health products industry.

4. Cambrian Bio

• Website: cambrianbio.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: July 2023
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: cambrianbio

Cambrian Bio, founded in 2019 and based in New York, is a biotechnology company dedicated to creating innovative therapeutics for chronic diseases and age-related conditions. The company collaborates with scientists to advance drug development, with a particular emphasis on extending healthspan. Cambrian Bio operates as a clinical-stage drug development entity, actively working on multiple scientific breakthroughs that target the biological drivers of aging. Their approach involves developing treatments that first address specific diseases, with the ultimate goal of deploying these as preventive therapies. Cambrian Bio's commitment to making transformative therapies widely available reflects their mission to improve the quality of life for individuals globally. They have a small team of around 27 employees and have recently engaged in financing activities to support their initiatives.

5. American Regent, Inc.

• Website: americanregent.com
• Ownership type: Private
• Headquarters: Shirley, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1910
• Headcount: 501-1000
• LinkedIn: americanregent

American Regent, Inc., founded in 1910 and based in Shirley, New York, is a private pharmaceutical company that specializes in the manufacturing and distribution of injectable medications. With a workforce of approximately 852 employees, the company plays a vital role in supplying essential products to healthcare providers and institutions. American Regent is particularly focused on addressing drug shortages, collaborating with the FDA to mitigate these issues that can impact patient care. Their product portfolio includes a range of injectable medications, such as Epinephrine and Sodium Phosphates, which are crucial for various medical treatments. Recently, the company has expanded its offerings through a partnership with HBT Labs, aiming to enter the oncology market and enhance its product range. American Regent's commitment to quality and patient care is further underscored by its recognition from Vizient, Inc., showcasing its dedication to improving healthcare outcomes.

6. Epic Pharma

• Website: epic-pharma.com
• Ownership type: Corporate
• Headquarters: Queens, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $550.0M, March 2016
• Founded year: 2008
• Headcount: 201-500
• LinkedIn: epic-pharma

Epic Pharma, LLC is a pharmaceutical manufacturer based in Queens, New York, established in 2008. The company specializes in the development and production of generic prescription drugs, catering to healthcare providers and pharmacies. Epic Pharma operates a fully functional FDA-approved manufacturing facility that spans 110,000 square feet and employs around 200 individuals. The company is dedicated to maintaining high standards in quality and customer satisfaction, utilizing state-of-the-art technology and machinery in its operations. Epic Pharma's product portfolio includes a variety of medications in tablet, capsule, and powder forms, addressing multiple therapeutic categories. Additionally, the company offers contract manufacturing services, highlighting its expertise in producing controlled substances and its ability to meet the needs of larger pharmaceutical companies. With a focus on innovation and quality, Epic Pharma continues to expand its product offerings, contributing to the healthcare community by providing affordable medication options.

7. Sanavia Oncology Inc.

• Website: sanavia.bio
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: sanavia-oncology

Sanavia Oncology Inc. is a New York-based biotechnology firm founded in 2020, dedicated to the development of innovative immunotherapies for drug-resistant cancer. The company is staffed by a team of experienced drug developers hailing from prestigious institutions such as Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine, and Columbia University. Sanavia's mission centers on enhancing patient outcomes by tackling the issue of drug resistance, which affects a significant number of cancer patients who do not benefit from existing therapies. Their approach combines advanced scientific research with breakthrough technologies, including high throughput sequencing and artificial intelligence, to validate targets and create effective immunotherapies. Sanavia's proprietary platform focuses on discovering clinically relevant, cancer-specific epitopes, allowing them to generate antibodies with high specificity for drug-resistant tumors. This patient-centered approach, combined with their commitment to collaboration with healthcare professionals, underscores their role in advancing oncology.

8. Igi

• Website: iginnovate.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Switzerland 75%, United States (USA) 16%, India 9%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: ichnos-sciences

Ichnos Glenmark Innovation (IGI) is a biotechnology firm based in New York, New York, that specializes in creating innovative therapies for cancer treatment. Established in 2019, IGI is dedicated to developing solutions for both hematological malignancies and solid tumors. The company operates with a strong emphasis on research and development, leveraging a proprietary protein engineering platform to create multispecific antibodies. Their pipeline includes several promising candidates currently in Phase 1 trials, such as ISB 1442 and ISB 2001, which target specific cancer markers. IGI collaborates with various partners in the healthcare sector to enhance its research capabilities and drive forward its mission of improving patient outcomes in oncology. With a workforce of approximately 156 employees, IGI maintains a global presence with centers of innovation in the USA, Switzerland, and India, reflecting its commitment to advancing cancer therapies on an international scale.

9. XGen Pharmaceuticals DJB

• Website: xgenpharmadjb.com
• Ownership type: Family Owned
• Headquarters: Big Flats, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2003
• Headcount: 51-200
• LinkedIn: x-gen-pharmaceuticals-inc

XGen Pharmaceuticals DJB, Inc. is a pharmaceutical company based in Big Flats, New York, that specializes in the manufacturing and distribution of generic medications. Established in 2003, the company has built a reputation for providing a wide range of injectable pharmaceuticals aimed at healthcare providers, hospitals, and pharmacies. With a workforce of approximately 62 employees, XGen Pharmaceuticals DJB emphasizes its mission to deliver affordable medications that enhance and save lives across various therapeutic categories. The company has a strong commitment to quality and compliance, as evidenced by its accreditation from the National Association of Boards of Pharmacy (NABP) in May 2022. This accreditation highlights their dedication to maintaining high standards in the pharmaceutical industry. XGen's product catalog includes a variety of injectable medications, showcasing their focus on addressing specific medical needs. Their proactive approach to regulatory compliance, including adherence to the Drug Supply Chain Security Act (DSCSA), further solidifies their position in the pharmaceutical landscape.

10. Kallyope

• Website: kallyope.com
• Ownership type: Private Equity
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $8.2M, May 2023
• Founded year: 2015
• Headcount: 51-200
• LinkedIn: kallyope

Kallyope is a biopharmaceutical company based in New York City, founded in 2015. The company is dedicated to discovering and developing novel oral therapeutics that target significant health challenges, particularly in the areas of metabolic, neurological, and gastrointestinal diseases. Kallyope operates through its proprietary Klarity™ platform, which combines various technologies to enhance drug discovery and development processes. Their research focuses on conditions such as obesity, type 2 diabetes, migraines, and gastrointestinal disorders like celiac disease. Kallyope has made strides in advancing its pipeline, with a commitment to addressing unmet medical needs. The company has also secured funding, including an $8.2 million grant in May 2023, to support its initiatives aimed at improving human health. With a team of experienced scientists and drug developers, Kallyope is positioned to make significant contributions to the pharmaceutical industry.

11. ScieGen Pharmaceuticals Inc

• Website: sciegenpharm.com
• Ownership type: Private
• Headquarters: Hauppauge, New York, United States (USA)
• Employee distribution: United States (USA) 84%, India 16%
• Founded year: 2010
• Headcount: 201-500
• LinkedIn: sciegen-pharmaceuticals-inc

ScieGen Pharmaceuticals Inc, based in Hauppauge, New York, is a private pharmaceutical company that specializes in the development, manufacturing, and distribution of generic pharmaceutical products. Founded in 2010, ScieGen aims to provide high-quality and cost-effective medications to healthcare providers and patients, ensuring that essential drugs are accessible. The company operates state-of-the-art manufacturing facilities in the United States, which comply with stringent cGMP standards. ScieGen has a strong product development pipeline, with over 60 ANDAs filed and more in progress, showcasing its commitment to expanding its portfolio. The company also emphasizes quality assurance and regulatory compliance, which are critical in the pharmaceutical industry. With a workforce of around 164 employees, ScieGen maintains a significant presence in the market, particularly in the generic drug sector.

12. Chartwell Pharmaceuticals

• Website: chartwellpharma.com
• Ownership type: Private
• Headquarters: Congers, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2010
• Headcount: 51-200
• LinkedIn: chartwell-pharmaceuticals

Chartwell Pharmaceuticals LLC is a pharmaceutical company based in Congers, New York, founded in 2010. The company specializes in the development and manufacturing of generic medications, catering to healthcare providers and organizations. Chartwell aims to ensure that patients have access to affordable pharmaceutical products. The company has built a strong product pipeline, with over 700 Orange Book listings and a commitment to launching more than 20 products in the coming months. Their operations are compliant with government regulations, and they actively seek partnerships to enhance their capabilities. The leadership team at Chartwell boasts extensive experience in the pharmaceutical industry, which supports their strategic initiatives and operational effectiveness.

13. Menarini Stemline

• Website: stemline.com
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 59%, Italy 10%, Germany 5%, Other 26%
• Latest funding: $677.0M, May 2020
• Founded year: 2003
• Headcount: 501-1000
• LinkedIn: stemline-therapeutics-inc-

Menarini Stemline, a part of the Menarini Group, is a biopharmaceutical company based in New York City. Founded in 2003, the company specializes in the development and commercialization of innovative oncology therapeutics. Their product offerings include ELZONRIS (tagraxofusp-erzs), which is approved for treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), and ORSERDU (elacestrant), aimed at treating advanced breast cancer. Menarini Stemline is dedicated to improving patient outcomes through targeted therapies and is actively engaged in clinical trials to expand their product pipeline. The company has received significant funding, amounting to $677 million in 2020, which supports their ongoing research and development efforts in oncology. With a focus on addressing serious medical needs, Menarini Stemline is positioned as a notable entity in the pharmaceutical sector.

14. Fera Pharmaceuticals

• Website: ferapharma.com
• Ownership type: Corporate
• Headquarters: Locust Valley, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: June 2013
• Founded year: 2009
• Headcount: 11-50
• LinkedIn: fera-pharmaceuticals

Fera Pharmaceuticals, founded in 2009 and based in Locust Valley, New York, is a specialty pharmaceutical company dedicated to developing and manufacturing essential ophthalmic medications. The company primarily focuses on niche and orphan conditions, ensuring that healthcare providers and patients have access to vital therapies. Their flagship product, Phospholine Iodide, is used to treat elevated intraocular pressure and accommodative esotropia, conditions that can significantly impact vision. Fera has taken over the production of this medication after its discontinuation by Pfizer in 2021, demonstrating their commitment to maintaining critical treatment options. In addition to Phospholine Iodide, Fera is actively working on expanding its product pipeline, which includes several FDA-approved ophthalmic treatments and orphan drugs currently in development. Their approach emphasizes collaboration and partnerships to enhance treatment options and address unmet medical needs in the pharmaceutical landscape.

15. Abon Pharmaceuticals, LLC

• Website: abonpharma.com
• Ownership type: Private
• Headquarters: Chestnut Ridge, New York, United States (USA)
• Employee distribution: United States (USA) 89%, United Kingdom (UK) 5%, Portugal 5%
• Founded year: 2009
• Headcount: 11-50
• LinkedIn: abon-pharmaceuticals-llc

Abon Pharmaceuticals, LLC, based in Chestnut Ridge, New York, is a private pharmaceutical company established in 2009. The firm specializes in the development of complex generics and proprietary products, particularly in injectable and oral dosage forms. Abon emphasizes a science-based approach to product development, integrating rigorous research and modern technology to improve drug delivery systems. Their recent achievements include receiving FDA approval for a generic version of Carafate® (sucralfate) oral suspension, which is expected to capture a significant share of the market. The company operates with a commitment to quality and patient compliance, serving healthcare providers and pharmaceutical companies seeking innovative solutions. With a team of experienced professionals, Abon has generated multiple patents and continues to explore partnerships for manufacturing and distribution of its products.

16. Saptalis Pharmaceuticals,LLC

• Website: saptalis.com
• Ownership type: Private
• Headquarters: Hauppauge, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $6.5M, November 2016
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: saptalis-pharmaceutcals-llc

Saptalis Pharmaceuticals, LLC is a pharmaceutical company based in Hauppauge, New York, specializing in the development, manufacturing, and commercialization of niche generic and innovative products. Founded in 2015, Saptalis has built a growing portfolio of prescription medications, utilizing regulatory pathways such as ANDA and 505(b)(2). The company is dedicated to providing high-quality, affordable medicines to healthcare providers and patients, addressing specific medical needs. Saptalis operates state-of-the-art facilities for the development and manufacturing of oral liquid and topical cream products, ensuring compliance with FDA cGMP standards. Their recent FDA approvals, including Lithium Oral Solution and Metronidazole Oral Suspension, highlight their active role in the pharmaceutical industry. With a focus on innovation and quality, Saptalis aims to improve patient outcomes through its product offerings.

17. Itb-med

• Website: itb-med.com
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Sweden 53%, United States (USA) 47%
• Latest funding: $67.0M, April 2018
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: itbmed-ab

ITB-MED, founded in 2016 and based in New York City, is a biotechnology firm dedicated to creating innovative therapies for transplantation and autoimmune diseases. The company is advancing its proprietary monoclonal antibody, TCD601 (siplizumab), through extensive global clinical trials. This therapy aims to improve patient outcomes by potentially eliminating the need for lifelong immunosuppression, which is a common requirement after organ transplants. ITB-MED's focus on enhancing the quality of life for transplant patients and reducing healthcare costs reflects its commitment to addressing significant medical challenges. The company has a workforce of approximately 55 employees, with a notable presence in both the United States and Sweden. In 2018, ITB-MED secured $67 million in funding, which underscores its potential and the interest it has garnered within the biotechnology and pharmaceutical sectors.

18. Liptis Usa

• Website: liptisusa.net
• Ownership type: Private
• Headquarters: Spring Valley, New York, United States (USA)
• Employee distribution: Egypt 83%, Libya 11%, Saudi Arabia 3%, Other 3%
• Founded year: 1995
• Headcount: 201-500
• LinkedIn: liptis-usa

Liptis USA, established in 1995 and headquartered in Spring Valley, New York, is a private pharmaceutical company focused on manufacturing innovative products that enhance human health and well-being. The company offers a range of pharmaceutical and nutraceutical products, including JointGuard and Stamigen, which specifically target conditions like osteoarthritis. Liptis USA serves healthcare professionals and patients seeking effective treatments, showcasing their commitment to improving quality of life. With a workforce of approximately 66 employees, the company operates in various countries, primarily in the Middle East and North Africa, indicating a broad market reach. Their involvement in industry conferences, such as the EOA/SICOT Conference, highlights their active role in the pharmaceutical sector and their dedication to staying connected with healthcare advancements.

19. Gilgamesh Pharmaceuticals

• Website: gilgameshpharmaceutical.com
• Ownership type: Private Equity
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $14.0M, March 2024
• Founded year: 2019
• Headcount: 1-10
• LinkedIn: gilgamesh-pharmaceuticals

Gilgamesh Pharmaceuticals is a clinical-stage biotechnology firm based in New York, founded in 2019. The company is dedicated to developing innovative therapies specifically targeting mental health disorders. Their research focuses on creating new chemical entities (NCEs) that aim to address the root causes of conditions such as depression and opioid use disorder, rather than merely managing symptoms. Gilgamesh employs advanced research techniques, including an AI-powered discovery platform, to optimize their drug candidates. They have a robust pipeline that includes several promising candidates currently in clinical trials, such as GM-1020, an oral NMDAR antagonist, and GM-2505, a short-acting 5-HT2A agonist. The company has received notable funding, including a $14 million grant from the National Institute on Drug Abuse, to advance their research efforts. Their team comprises experienced professionals from top biopharmaceutical companies and academic institutions, underscoring their expertise in the field.

20. Jerome Stevens Pharmaceuticals, Inc.

• Website: jeromestevens.com
• Ownership type: Family Owned
• Headquarters: Bohemia, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1976
• Headcount: 51-200
• LinkedIn: jspinc

Jerome Stevens Pharmaceuticals, Inc. is a family-owned pharmaceutical manufacturer based in Bohemia, New York. Founded in 1976, the company has carved out a niche in the production of prescription medications. It is particularly recognized for its flagship products, Unithroid and Digoxin, which are essential for managing hypothyroidism and heart failure, respectively. The company prides itself on its rigorous manufacturing processes, ensuring that safety and quality are never compromised. Over the years, JSP has transitioned from manufacturing vitamins and over-the-counter products to focusing on prescription medications, achieving FDA approval for Unithroid in 2000 as the first branded Levothyroxine product. This milestone established JSP as a reference point in the treatment of thyroid conditions. The company operates exclusively within the United States and continues to innovate while adhering to high standards of pharmaceutical manufacturing.

21. Stablix, Inc.

• Website: stablix.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $63.0M, June 2021
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: stablix

Stablix, Inc. is a biotechnology firm based in New York City and Boston, founded in 2021. The company specializes in targeted protein stabilization and deubiquitination therapeutics, aiming to develop innovative small-molecule medicines that restore protein function for various diseases, including cancer and rare disorders. Their RESTORED™ platform employs advanced scientific methods to create therapeutic solutions, which are not only applicable to oncology but also to immunological disorders and rare diseases. Stablix has garnered significant attention in the industry, being named one of FierceBiotech's 'Fierce 15' companies in 2021. The company successfully raised $63 million in a Series A funding round, led by prominent investors such as Versant Ventures and New Enterprise Associates. This funding is intended to support their research and development efforts as they advance their lead programs toward clinical studies.

22. Celmatix Therapeutics

• Website: celmatix.com
• Ownership type: Private Equity
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $3.5M, October 2024
• Founded year: 2009
• Headcount: 11-50
• LinkedIn: celmatix

Celmatix Therapeutics, founded in 2009 and based in New York, is a biotechnology firm dedicated to advancing women's health through innovative drug therapies. The company specializes in conditions related to ovarian health, such as polycystic ovary syndrome (PCOS) and endometriosis. Celmatix has developed the largest structured dataset on ovarian health, which informs their drug discovery and development processes. They collaborate with leading reproductive health centers and have partnerships with pharmaceutical giants like Bayer and Evotec to enhance their research capabilities. Recently, Celmatix secured $3.5 million in funding, demonstrating ongoing investor interest in their mission to transform women's health through better therapeutic options. Their pipeline includes novel drug programs aimed at addressing critical gaps in treatment for various women's health issues.

23. Intrommune Therapeutics

• Website: intrommune.com
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, February 2022
• Founded year: 2015
• Headcount: 1-10
• LinkedIn: intrommune-therapeutics

Intrommune Therapeutics, based in New York, is a healthcare company founded in 2015 that specializes in developing innovative treatments for food allergies, with a primary focus on peanut allergies. The company is pioneering a product known as Peanut INT301, which utilizes a novel oral mucosal immunotherapy (OMIT) platform. This platform allows for the delivery of therapeutic agents embedded in a toothpaste, making it a convenient daily treatment for patients. With over 32 million Americans affected by food allergies, Intrommune aims to provide a safe and effective solution that can help alleviate the anxiety associated with accidental exposure to allergens. The company is currently advancing its clinical trials, including the Phase 1 OMEGA Clinical Trial, to assess the safety and efficacy of its product. Intrommune's approach not only addresses a critical health issue but also reflects a commitment to innovation in the pharmaceutical industry.

24. Capsule

• Website: capsule.com
• Ownership type: Private Equity
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, $300.0M, April 2021
• Founded year: 2016
• Headcount: 501-1000
• LinkedIn: capsule-co

Capsule is a New York-based pharmacy founded in 2016, dedicated to transforming the pharmacy experience for consumers. The company provides both prescription and over-the-counter medications, focusing on making it easier for individuals to access their medications and pharmacy services. Capsule's innovative approach includes a user-friendly platform that streamlines the ordering process, ensuring timely delivery and enhanced customer service. With a workforce of approximately 813 employees, Capsule has garnered significant attention and investment, securing $300 million in funding as of April 2021. This financial backing underscores their commitment to growth and their role in the pharmaceutical industry, particularly in the realm of medication distribution and patient engagement.

Pharmaceuticals Insights: Key Companies in New York

Want to Find More Pharmaceuticals Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!